drugset / Trial / NCT06495463

Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan

NCT06495463

Unknown 110 enrolled Chang Gung Memorial Hospital
NaSingle-groupOpen-labelTreatment

Summary

Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile

Timeline

Start
2022-03-19
Primary completion
2024-08-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 100 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Tipiracil Small molecule 35 mg/m2 Oral
Subject Trifluridine Small molecule 35 mg/m2 Oral

Indications